Building a strong EIC Accelerator application for Lipisense - first-in-class therapy for lipid related disorders
| Reference number | |
| Coordinator | Lipigon Pharmaceuticals AB |
| Funding from Vinnova | SEK 299 705 |
| Project duration | July 2023 - October 2023 |
| Status | Completed |
| Venture | Preparation projects for international application within health |
| Call | Preparation project for international proposal in health and food 2023 |
Important results from the project
The objective of this project was to get support from Vinnova in applying for funding from EIC Accelerator. We seek EIC Accelerator support to get a clinical PoC and safety of our drug candidate Lipisense by completing a small phase II study in severe hypertriglyceridemia and type 2 diabetes and in a phase II a/b trial in the same category of patients for evaluation of the safety profile and efficacy in depth. With the support from Vinnova, we pursued our goals which were defining a detailed workplan, strengthening our IP strategy, go-to-market plan and preparing a strong EIC application.
Expected long term effects
As a result of the project, Lipigon submitted step 1 application to the EIC Accelerator call. With a positive verdict for step 1, Lipigon has worked to prepare a competitive step 2 application which will be submitted before 8th of November. The outcome of the support from Vinnova include a detailed work plan with optimized timetable. An updated Freedom to operate analysis. Recruiting identified partners and resources needed for the successful execution of the EIC project. Providing a go-to-market plan with financial forecasts based on target markets data.
Approach and implementation
The project was conducted over the course of 11 weeks between 17/07/2023 and 01/10/2023. The work was organized into four work packages: WP1 Detailed planning of specific work packages WP2 IP strategy and Freedom to Operate WP3 Business plan and go-to-market strategy WP4 Strong EIC application The work packages run in parallel and were executed by the Lipigon team (WP1, WP2, WP3) and with the support from a qualified grant consultancy (WP4).